Biotechnology

'Wobbling risk appetite'

INDUSTRY VOICE: Despite market volatility in Q1, BB Biotech performed very well with an overall return of 8.8% in CHF. Several large biotech companies are currently trading below their fundamental value,and offer an attractive entry level for investors....

Sustainability in focus

Focus on technology

2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and BB Biotech's holdings in focus. The investment team expects new product launches...

With a total return of 23.1% in CHF and 13.1% in EUR buoyed by the euro's substantial appreciation against the dollar, BB Biotech delivered a strong performance in 2017 and will propose a record regular dividend of CHF 3.30 per share .

Big sustainability challenges being tackled

Turnaround in the sector

TER of 0.35%

Alternative routes to dividend income